|
- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast . . .
Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the
- Inavolisib - Wikipedia
Inavolisib, sold under the brand name Itovebi by Genentech, a member of the Roche group, is an anti-cancer medication used for the treatment of breast cancer [4][7] It is an inhibitor and degrader of mutated phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)
- Genentech: Itovebi™ (inavolisib) - Information for Patients
Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine Ask about possible side effects and any other medical questions related to your prescribed Genentech medicine What is Itovebi?
- Inavolisib - NCI - National Cancer Institute
Inavolisib works by blocking the activity of a protein called PI3K-alpha that signals cells to multiply It also helps break down mutant (overactive) versions of this protein found in cancer cells
- Inavolisib (oral route) - Side effects dosage - Mayo Clinic
Inavolisib interferes with the growth of cancer cells, which are eventually destroyed Since the growth of normal cells may also be affected by the medicine, other unwanted effects will also occur
- Inavolisib Uses, Side Effects Warnings - Drugs. com
What is inavolisib? Inavolisib is used in combination with other cancer treatments to treat adults with breast cancer that has spread to other parts of the body (metastatic) and has come back after treatment with medicines
- Label - accessdata. fda. gov
Inavolisib is a white to off-white, greyish pink, greyish orange, or greyish yellow powder or powder with lumps Inavolisib demonstrates pH-dependent aqueous solubility; the greatest solubility
- MHRA Approves Inavolisib for PIK3CA-Mutated Breast Cancer
The MHRA has approved inavolisib for adults with PIK3CA-mutated HR+ HER2– breast cancer, offering a new targeted first-line therapy that significantly prolongs progression-free survival
|
|
|